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Background: Children below the age of six months suffer less often from malaria than older children in sub-Saharan
Africa. This observation is commonly attributed to the persistence of foetal haemoglobin (HbF), which is considered not
to permit growth of Plasmodium falciparum and therefore providing protection against malaria. Since this concept has
recently been challenged, this study evaluated the effect of HbF erythrocytes and maternal plasma on in vitro parasite
growth of P. falciparum in Central African Gabon.
Methods: Umbilical cord blood and peripheral maternal blood were collected at delivery at the Albert Schweitzer
Hospital in Gabon. Respective erythrocyte suspension and plasma were used in parallel for in vitro culture. In vitro
growth rates were compared between cultures supplemented with either maternal or cord erythrocytes. Plasma of
maternal blood and cord blood was evaluated. Parasite growth rates were assessed by the standard HRP2-assay
evaluating the increase of HRP2 concentration in Plasmodium culture.
Results: Culture of P. falciparum using foetal erythrocytes led to comparable growth rates (mean growth rate = 4.2,
95% CI: 3.5 – 5.0) as cultures with maternal red blood cells (mean growth rate =4.2, 95% CI: 3.4 – 5.0) and those from
non-malaria exposed individuals (mean growth rate = 4.6, 95% CI: 3.8 – 5.5). Standard in vitro culture of P. falciparum
supplemented with either maternal or foetal plasma showed both significantly lower growth rates than a positive
control using non-malaria exposed donor plasma.
Conclusions: These data challenge the concept of HbF serving as intrinsic inhibitor of P. falciparum growth in the first
months of life. Erythrocytes containing HbF are equally permissive to P. falciparum growth in vitro. However, addition of
maternal and cord plasma led to reduced in vitro growth which may translate to protection against clinical disease or
show synergistic effects with HbF in vivo. Further studies are needed to elucidate the pathophysiology of innate and
acquired protection against neonatal malaria.
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Although children below five years of age are dispropor-
tionally severely affected by malaria morbidity and mor-
tality, there is a lag time of about three months after
birth, before first disease episodes occur [1-4]. This
period coincides with the persistence of maternal IgG
antibodies in the infant’s circulation but other protective* Correspondence: michael.ramharter@medizin.uni-tuebingen.de
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tibility [4-7].
Previous studies postulate a role for persisting foetal
haemoglobin during the first months of life in protection
against malaria [8]. The transcription of HbF starts
around the 10th week of development and ends shortly
before birth. This causes a linear decline in the number
of foetal red blood cells from up to 90% at time of birth
to around 5% at 3 months of age [8]. It was hypothesized
that parasite strains – encountering HbF only on rela-
tively rare occasions from an evolutionary perspective –
may therefore be selected by strong adaptation to adultral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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erythrocytic growth of Plasmodium falciparum in pre-
dominantly HbF containing neonatal blood [9,10]. This
paradigm of protection during early infancy – first pub-
lished in 1977 – was held up since then until recently,
when Amaratunga et al. failed to detect growth delays in
neonatal erythrocytes and thus profoundly challenged
this concept [11].
To further investigate potential mechanisms of protec-
tion, this study evaluated the comparative in vitro
growth rates of a standardized P. falciparum clone under
controlled culture conditions using either maternal,
cord, or non-malaria exposed donor erythrocytes.
In addition, the growth modulating effect of maternal,
cord, and non-malaria exposed donor plasma on P. falcip-
arum growth was evaluated.
Methods
Study region and patient population
The study took place at the Centre de Recherches
Médicales de Lambaréné, Albert Schweitzer Hospital and
Georges Rawiri Regional Hospital in Lambaréné, Gabon.
Gabon is a Central African country characterized by a trop-
ical climate and hyperendemic malaria transmission [12].
Participants were invited to join this study when attending
the local maternity wards for delivery. Demographic data
were obtained, however no validated information about in-
take of IPTp was available. All subjects were tested in rou-
tine antenatal care for HIV and only those with negative
test result were invited to participate. The study protocol
was approved by the institutional review board of the CER-
MEL and the ethical review committee of the Medical
University of Vienna and all women provided written in-
formed consent prior to blood sampling.
All samples were tested for sickle cell trait by haemoglo-
bin electrophoresis and for plasmodial infection by thick
smear at the time of delivery and samples were excluded in
case of a positive result or when signs of haemolysis or clot-
ting were apparent. At delivery 1.2 ml of blood was taken
from the umbilical cord in an EDTA tube. Peripheral ma-
ternal venous blood was taken at the earliest convenience
within three days. Non-malaria exposed donor blood was
obtained from Caucasian male volunteers. Blood samples
were collected in EDTA tubes and specimens were immedi-
ately centrifuged to separate red blood cells from plasma.
Red blood cells were washed three times in complete para-
site medium and stored at 4°C in 0.5 volume of saline aden-
ine glucose-mannitol (150 mM NaCl, 1.25 mM adenine,
45 mM glucose, 30 mM mannitol) until further use. Plasma
was immediately frozen at −80°C.
Parasite culture and growth assay
A laboratory-adapted clone of P. falciparum (3D7) re-
peatedly selected for presence of knob-phenotype waskept in continuous sorbitol synchronized culture through-
out the course of the study. Parasites were maintained
using a standard protocol in complete parasite medium
(500 ml RPMI-1640, 10 mg/l gentamicin, 6 g/l (25 mM)
HEPES, 292 mg/l (2 mM) L-glutamine, 50 mg/l (0.36 mM)
hypoxanthine, 5 g/l Albumax II) in a candle jar at 37°C. To
test the effect of erythrocytes and plasma on plasmodial
growth, micro-cultures of 200 μl each were established in
96-well plates (Corning Costar-3599) in duplicates. To in-
vestigate the effect of HbF on parasite growth, micro-
cultures containing cord derived red blood cells and mater-
nal red blood cells, respectively, as well as a positive control
containing donor O + red blood cells, were set up in dupli-
cates. Parasites derived from continuous culture in adult
RBC were diluted with respective test RBC (>1 : 40) to ob-
tain at 1.5% haematocrit, 0.05% parasitaemia using 5%
pooled, heat inactivated serum from AB+ donors for
72 hours before growth was stopped by freezing.
Plasma derived from mothers, newborns and a malaria-
naïve adult was added to cultures in complete parasite
medium to assess its effect on parasite growth at 1.5%
haematocrit, 0.05% parasitaemia and 10% plasma supple-
mentation. Frozen lysates of micro-cultures were used for
histidine-rich protein II enzyme linked immunosorbent
assay (HRP2 ELISA) for the quantification of parasite
growth [13-15]. Commercial antibodies (MPFM-55A and
MPFG-55P, Immunology Consultants Laboratories, Inc)
and high binding plates (Corning Costar 3590) were used.
Growth rates of P. falciparum were estimated by the as-
sessment of HRP2 concentrations in cultures. Growth was
defined as an increase in optical density in the HRP2
ELISA. An at least two fold increase in HRP2 concentra-
tion from prior to post incubation was set as threshold for
further analysis. Statistical analysis was performed using
“R” software. Differences between groups were assessed
employing the Tukey's Honestly Significant Difference
test. All reagents, unless stated otherwise were obtained
from Sigma-Aldrich, St. Louis.
Results
Hundred and three pregnant women consented to par-
ticipate in this study between July 2012 and June 2013,
of which sixty-five were excluded from further testing
(sickle cell trait: 12, clotting: 27, haemolysis after sam-
pling: 13, Plasmodium infection: 7, presence of anti-
Rhesus antibodies: 6). Thirty-eight participants finally
met the criteria for analysis. Mother's age was ranging
from 17 to 42 years with a mean of 25 years and a stand-
ard deviation of 7.1 years with a mean gravidity of 3.5
with a standard deviation of 2.4. Mean gestational age at
delivery was 38.5 weeks of gestation with a standard
deviation of 2.1 weeks and mean birth weight was 2,866
grams ranging from 1,900 to 4,400 grams. Among the
recruited women, 18 paired erythrocyte samples and 22
Figure 1 In vitro growth rates of Plasmodium falciparum when using cord, maternal or non-malaria exposed donor erythrocytes
displayed by data points, means and 95% CIs.
Table 1 Mean growth rates and lower and upper margin
of 95% CIs in test given test erythrocytes of high and low





Cord derived RBC 3.50 4.23 4.97
Maternal RBC 3.38 4.19 5.00
Non malaria exposed donor RBC 3.79 4.63 5.47
Low growth
Cord derived RBC 4.63 5.36 6.08
Maternal RBC 4.63 5.43 6.23
Non malaria exposed donor RBC 5.42 6.09 6.76
High growth
Cord derived RBC 3.01 3.11 3.21
Maternal RBC 2.81 2.95 3.10
Non malaria exposed donor RBC 3.02 3.17 3.33
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further in vitro testing.
Maternal, neonatal, and non-malaria exposed donor
erythrocytes
Parasite growth was quantified by HRP2 ELISA. 18 paired
samples of maternal, cord and donor RBCs showed ad-
equate growth and were used for comparative evaluation.
Mean cumulative growth rates were 4.35 (95% confidence
interval: 3.90 – 4.81) folds when compared with pre-
incubation samples. No significant difference between cul-
tures using non-malaria exposed donor erythrocytes
(mean growth rate: 4.6, 95% CI: 3.8 – 5.5) or either mater-
nal (4.2, 95% CI: 3.4 – 5.0) or cord derived erythrocytes
(4.2, 95% CI: 3.5 – 5.0) was observed (Figure 1). Similarly,
growth rates between maternal and cord derived erythro-
cytes supplemented cultures did not differ (p = 0.99). To
test these findings under different culture conditions, cul-
tures were classified in high growth (>4 fold increase) and
low growth strata (2–4 fold increase in HRP2). When
comparing growth rates within these strata, again no sig-
nificant difference was observed (Table 1).
In addition to this quantitative analysis, a qualitative
analysis of intra-erythrocytic growth of P. falciparum
was performed microscopically. Parasites growing in
umbilical cord erythrocytes displayed microscopically
similar maturation characteristics and no other obvious
morphological differences were observed (Figure 2).
Maternal, neonatal, and non-malaria exposed plasma
Growth rates of P. falciparum were compared under
standard conditions by supplementing culture medium
with either maternal or cord derived plasma and non-
malaria exposed donor plasma serving as a positive con-
trol. Plasmodium falciparum growth was significantlyhigher in non-malaria exposed donor plasma containing
culture medium than in either culture supplemented
with test plasma (Figure 3). Whereas the mean increase
in HRP2 concentration in culture supplemented with
malaria-naïve plasma was 6.8 fold, growth rates in cul-
tures supplemented with maternal and umbilical cord
plasma averaged 2.1 fold (p <0.001). Umbilical cord
plasma (mean growth rate: 2.1, 95% CI: 2.0 - 2.3) and
maternal plasma (mean growth rate: 2.1, 95% CI: 2.0 -
2.2) yielded close to identical results. (p =0.93)
Discussion
This study demonstrates that cord derived erythrocytes,
harbouring a high concentration of HbF, are equally
suited for P. falciparum invasion, maturation, and
growth as adult erythrocytes containing predominantly
Figure 2 In-vitro development of Plasmodium falciparum over time in erythrocytes rich in foetal and adult haemoglobin respectively.
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non-malaria exposed donor erythrocytes were very simi-
lar, and no morphological signs of growth inhibition
were detected. These findings provide strong evidence
that P. falciparum may similarly develop within HbF
rich red blood cells and that HbF per se is no protective
factor against malaria during the first months of life.
These data are in line with results published by
Amaratunga et al. [11] demonstrating normal invasion
and development of P. falciparum in HbF containing
red blood cells in a set of adult and six cord blood speci-
mens. While this study focused on an overall assessment
of parasite growth in a larger sample size, Amaratunga
et al. could detect effects of neonatal haemoglobin, in
particular in conjunction with immune IgGs, on the knob
phenotype and PfEMP-1 mediated cytoadherence of para-
sitized red blood cells. Although erythrocytes rich in foetal
haemoglobin seem to be permissive to infection with
P. falciparum in vitro, reduced cytoadherence may, par-
ticularly in the presence of IgG, lead to lower parasite
densities in vivo due to increased clearance of infected
cells in the spleen.
To evaluate whether humoral immunity and transfer
of maternal immunoglobulins or other plasmatic factorsFigure 3 In vitro growth rates of Plasmodium falciparum when supplem
points, means and 95% CIs. Non-malaria exposed donor plasma used as a pmay play a protective role in newborns, cultures were
supplemented with the respective plasma samples. Inter-
estingly, a consistent growth-inhibition was observed in
both maternal and neonatal plasma when compared to
non-malaria exposed donor plasma. In vitro growth
inhibition caused by a supplementation with immune
plasma was reported previously in Thai individuals yield-
ing comparable results to this study [16].
It is tempting to speculate that passive transfer of ma-
ternal antibodies to the newborn accounts for this
growth inhibitory effect. However, it may not be excluded
that other factors including cytokines, hormones, comple-
ment or indeed drugs with anti-malarial activity passing the
placental barrier into the neonatal blood may have caused
this inhibition of growth. One limitation of this study is the
lack of valid information about IPTp intake of study partici-
pants – a factor potentially affecting plasma assays. In
addition these data derive from experiments with one clone
of P. falciparum and potential differences between wild
isolates and laboratory adapted parasites may not be ruled
out. Finally, behavioural factors certainly also contribute
to young infants’ protection from malaria, since neonates
receive special care and attention by their caregivers poten-
tially leading to less exposure to infectious bites.ented with either cord or maternal plasma displayed by data
ositive control yielded a growth rate of 6.8, indicated by the vertical bar.
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infancy might yet be caused by the interplay of several
distinct factors, probably in conjunction with maternally
derived antibodies. However, these data conclusively re-
fute the hypothesis of HbF serving as an intrinsic inhibi-
tor of P. falciparum growth in vitro, and indicate that
maternal and newborn plasma show considerable inhibi-
tory activity against in vitro growth of P. falciparum.
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